Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 3, 2026

The Agentic Era Redefines Customer Intimacy as AI is Set to Become the Primary Brand Interface

View original at finance.yahoo.com
The Agentic Era Redefines Customer Intimacy as AI is Set to Become the Primary Brand Interface With AI agents leading customer interactions, new Amdocs global research shows CSPs must embed trust, transparency, and distinct personalities into every AI-led experience to drive the next generation of personalization JERSE…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 57% of CSPs today rely on a single AI persona, but only 11% expect that model to continue in the next one to two years

    80% confidence

  • AI agents are no longer just tools; they are becoming the living embodiment of the brand

    80% confidence

  • 56% of CSPs plan to deploy multiple predefined AI personalities in the next one to two years, up from 20% today

    80% confidence

  • Achieving true customer intimacy at scale is no longer just a marketing goal; it is a growth imperative

    80% confidence

  • In the Agentic Era, every AI-led interaction is a brand moment and brands must orchestrate AI personas with rigor and empathy

    80% confidence

  • CSP stakeholders expect most customer interactions to be AI-led within the next two years

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com